Cancer Therapies

G1 Therapeutics Inc (NASDAQ: GTHX), a clinical-stage biopharmaceutical company that focuses on novel oncology therapeutics, boasts three drug candidates that address "potential blockbuster" markets, according to H.C. Wainwright. The Analyst H.C. Wainwright's Edward White initiated...

Incyte Corporation (NASDAQ: INCY), a biopharmaceutical company that focuses on developing medications for the treatment of cancer, announced Friday a disappointing update to a phase 3 trial. What Happened Incyte said its experimental therapy called epacadostat failed in a phase 3 trial called...

Bluebird bio Inc (NASDAQ: BLUE), a clinical-stage biotechnology company that focuses on therapies for the treatment of severe diseases and cancer, released "highly encouraging" clinical data in late 2017, according to Janney. But that doesn't mean investors should be aggressive buyers...

Checkpoint Therapeutics Inc (NASDAQ: CKPT), a nano-cap therapeutics company that focuses on developing anti-cancer agents, has lost more than half of its value over the past few months but some analysts are bullish on the longer-term picture. The Analyst H.C. Wainwright's Joseph Joseph...

The U.S. Food and Drug Administration approved Wednesday Gilead Sciences, Inc. (NASDAQ: GILD)'s therapy for the treatment of non-Hodgkin's Lymphoma (NHL) called YESCARTA. The announcement helped boost Gilead's stock higher by more than 1 percent Thursday, yet some on Wall Street aren't ready to...

Shares of Puma Biotechnology Inc (NASDAQ: PBYI) soared higher by more than 70 percent on Monday after the U.S. Food and Drug Administration posted briefing documents ahead of the regulatory body's review of Puma's PB272 (neratinib) for the extended adjuvant treatment of HER2-positive early stage...

Shares of HTG Molecular Diagnostics Inc (NASDAQ: HTGM) soared higher by more than 60 percent early Thursday morning after the molecular profiling company confirmed regulatory approval for its products in Europe. HTG Molecular announced that it has obtained CE marking in the European Union for its...

Merck & Co., Inc. (NYSE: MRK)'s KEYTRUDA is a therapy used to combat a form of skin cancer called melanoma. It can also be used to treat a kind of lung cancer called non-small cell lung cancer. The U.S. Food and Drug Administration announced on Nov. 28, 2016, it has granted a Priority Review...

Transgenomic Inc (NASDAQ: TBIO), a nano-cap biotechnology engaged in advancing personalized medicine for the detection and treatment of cancer, skyrocketed higher by 295 percent Thursday. Transgenomic's stock gained $0.84 per share Thursday and closed at $1.12 after hitting an intra-day high of $1....

Shares of Clovis Oncology Inc (NASDAQ: CLVS) soared higher by more than 15 percent Monday after the U.S. Food and Drug Administration granted an accelerated approval for the company's PARP inhibitor rucaparib for the treatment of women with advanced ovarian cancer which will now be branded...

Shares of TESARO Inc (NASDAQ: TSRO) were trading higher by more than 12 percent early Monday morning after the company reported encouraging results from its niraparib Phase 3 NOVA clinical trial results. The trial was designed to assess the progression free survival rate among 553 patients...